Vaxcyte Inc. (PCVX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PCVX Stock Price Chart Interactive Chart >
PCVX Price/Volume Stats
|Current price||$43.02||52-week high||$47.67|
|Prev. close||$43.22||52-week low||$16.78|
|Day high||$43.39||Avg. volume||585,235|
|50-day MA||$36.35||Dividend yield||N/A|
|200-day MA||$27.26||Market Cap||3.40B|
Vaxcyte Inc. (PCVX) Company Bio
Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.
Most Popular Stories View All
PCVX Latest News Stream
|Loading, please wait...|
PCVX Latest Social Stream
View Full PCVX Social Stream
Latest PCVX News From Around the Web
Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.
E ratio of -17.15.
-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug
SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology ConferenceNovember 14-15, 2022 Fireside Chat will take place live on Monday, November 14 at 1:35
The growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.
Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week
Every investor in Vaxcyte, Inc. ( NASDAQ:PCVX ) should be aware of the most powerful shareholder groups. And the group...
PCVX Price Returns